SeaStar Medical (NASDAQ:ICU) Stock Price Down 2.3% – Here’s Why

SeaStar Medical Holding Co. (NASDAQ:ICU) was down 2.3% during trading on Thursday . The stock traded as low as $1.22 and last traded at $1.25. Approximately 43,547 shares were traded during trading, a decline of 83% from the average daily volume of 260,205 shares. The stock had previously closed at $1.28.

SeaStar Medical Stock Performance

The company has a market capitalization of $10.90 million, a P/E ratio of -0.11 and a beta of -0.93. The firm’s fifty day moving average is $1.71 and its 200-day moving average is $2.26.

SeaStar Medical (NASDAQ:ICU) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.01). The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.15 million.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in SeaStar Medical stock. Geode Capital Management LLC increased its stake in SeaStar Medical Holding Co. (NASDAQ:ICU) by 14.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,430 shares of the company’s stock after acquiring an additional 5,618 shares during the quarter. Geode Capital Management LLC owned about 1.02% of SeaStar Medical worth $88,000 at the end of the most recent reporting period. Institutional investors own 1.69% of the company’s stock.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.